A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effectiveness of the investigational
radioisotope Radium-223 in treatment of men with prostate cancer and bone metastases that no
longer respond to hormonal treatment.